```
IN THE UNITED STATES DISTRICT COURT
 1
             FOR THE NORTHERN DISTRICT OF OHIO
 2
                      EASTERN DIVISION
 3
 4
    IN RE: NATIONAL
                                 ) MDL No. 2804
    PRESCRIPTION OPIATE
 5
   LITIGATION
                                 ) Case No.
                                 ) 1:17-MD-2804
 6
    THIS DOCUMENT RELATES TO ) Hon. Dan A. Polster
 7
    ALL CASES
8
9
                    HIGHLY CONFIDENTIAL
10
  SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
11
12
                  VIDEOTAPED DEPOSITION OF
13
                       JOHN MERRITELLO
14
                      January 18, 2019
15
16
                      Chicago, Illinois
17
18
19
20
21
22
                 GOLKOW LITIGATION SERVICES
              877.370.3377 ph | 917.591.5672 fax
23
                        deps@golkow.com
24
```

8 BY THE WITNESS: I think you lost me a little bit --9 BY MR. SHKOLNIK: 10 11 Q. I'll rephrase it. 12 -- with a group coming from West 13 Virginia into some other state with a handful of 14 prescriptions. And a lot of cash. 15 Ο. 16 And a lot of cash and it's the same quy that's going to go around to a bunch of pharmacies. 17 He's committing a crime now, isn't he? 18 19 It's possible. But the fact --Q. 20 Terrible. Α. 21 But the fact of the matter is if you 22 have people willing to pay cash, I don't care if 23 it's Howard Hughes or John Smith from Main Street, if you have a group of people willing to pay cash 24

- and the store has two separate ceilings, one for
- 2 generic OxyContin and one for brand OxyContin, that
- would be a way for the store to sell upwards of
- 4 double of the OxyContin without triggering
- 5 ceilings --
- 6 MR. BENSINGER: Objection; foundation.
- 7 BY MR. SHKOLNIK:
- 8 Q. -- if you don't combine them?
- 9 MR. BENSINGER: Objection; foundation,
- 10 improper hypothetical.
- 11 BY THE WITNESS:
- 12 A. I'm going to have to argue with you
- because across the universe, the brand line would
- 14 be very, very low and even a prescription or two
- could put a store over its ceiling in a minute.
- 16 That number is going -- you're going to
- 17 be crawling -- that number is going to be crawling
- 18 along the bottom here without --
- MR. SHKOLNIK: Can you put that back up on the
- 20 screen, please.
- 21 BY THE WITNESS:
- 22 A. Oh.
- 23 BY MR. SHKOLNIK:
- Q. No, it's fine. I didn't realize it was

```
1 shut down.
```

- I gather what you're saying --
- MR. BENSINGER: Excuse me. Mr. Merritello,
- 4 had you finished your answer?
- 5 MR. SHKOLNIK: Oh, I'm sorry.
- 6 MR. BENSINGER: Could you read back the answer
- 7 and you let us know if you had finished or you were
- 8 interrupted.
- 9 MR. SHKOLNIK: I don't mean to cut you off.
- 10 (WHEREUPON, the record was read
- by the reporter as requested.)
- 12 BY THE WITNESS:
- 13 A. Let me rephrase just a little bit of
- 14 what I said.
- 15 BY MR. SHKOLNIK:
- 16 Q. Sure.
- 17 A. The regression line would be very, very,
- 18 very, very low. That number would be a very small
- 19 number. And if you filled a prescription of 30 or
- 20 60 and you did it twice, you're going to be sizably
- out of range for that branded item and it's going
- 22 to be reported back.
- 23 Q. Okay.
- 24 A. Okay? And the other, the generic line,

- 1 I would anticipate that under normal circumstances
- in a normal store would be much higher than that
- 3 branded item. So, the idea that you could double
- 4 there, I don't agree with that. I don't believe
- 5 you could do that.
- 6 Q. If I take out double, you could still
- 7 have increased sales by not combining the two
- 8 ceilings?
- 9 MR. BENSINGER: Objection; foundation,
- 10 improper hypothetical.
- 11 BY THE WITNESS:
- 12 A. A very slight one.
- 13 BY MR. SHKOLNIK:
- Q. And do you know what was happening in
- 15 Florida during the 2010 to 2012 time frame in terms
- of the numbers of pills that were being dispensed
- 17 at the Walgreens pharmacies? When I say pills, the
- 18 C-IIs, the controlled substances.
- 19 A. No, no, I can't recall that.
- 20 Q. If we can go to the next page, which is
- 21 619 of the PowerPoint. Here there's a description
- 22 and it says -- we know this PowerPoint is in
- January of 2013. The PowerPoint is now saying,
- "SOM version 5.5 is an industry leading enhancement

- 1 to SIMS."
- 2 Do you recall what 5.5 was?
- A. Not -- not off the top of my head. I'm
- 4 sorry.
- 5 Q. But by this point in time, your team had
- 6 already developed the ceiling algorithm, by 2013,
- 7 correct?
- A. I'll guess that 5.5 is referring to the
- 9 ceiling tool, the whole thing, including the
- dashboard for the integrity group and all of the
- 11 workings on the store AS400.
- 12 Q. And here it says, "Program enhancement
- to SIMS to impact ordering processes of all
- 14 controlled substances and PSE.
- 15 "Part of the calculations use an
- 16 accumulation of receipts of each controlled
- 17 substance over the last six weeks time."
- Was part of the analysis, I guess it's
- the regression model that's being utilized, did it
- 20 contemplate a six-week lookback or were you
- 21 contemplating some other -- did you consider other
- lookback periods in developing the algorithm?
- 23 A. So, when I went to the meeting and then
- there was subsequent meetings and an iteration with

- 1 programmers and design, that six-week is
- 2 configurable.
- 3 Six weeks was what I thought they ought
- 4 to start at, and I believe they are still using six
- 5 weeks today because that's recent enough history
- 6 and it actually is a complete six weeks. Today a
- 7 receipt comes in and six weeks go and a day, that
- 8 one comes out of that total that the store has
- 9 received in six weeks.
- 10 That's the -- that's the amount that
- 11 you're looking at. You're looking at a six-week
- 12 amount of receipts at that store pitted against the
- 13 whole chain.
- 14 Q. And so when you say six weeks receipts,
- 15 are we talking receipts buying from the
- 16 distribution center or receipts related to sales or
- 17 both?
- MR. BENSINGER: Objection.
- 19 BY THE WITNESS:
- 20 A. Receipts and sales, in my terminology,
- 21 we have to keep separate.
- 22 A receipt is an inbound from a vendor or
- from a distribution center or from another store,
- which is a no-no I think, but at points in time in

- 1 the past they had done that.
- 2 BY MR. SHKOLNIK:
- 3 Q. Understand.
- 4 A. Or they had buyouts from where we would
- 5 take over a pharmacy and we would induct a receipt
- 6 into the system.
- 7 All of those are considered receipts of
- 8 product as it's coming in the door.
- 9 Q. Okay. I'm glad you clarified.
- 10 A. Not sold. Not sold, though. That's
- 11 different.
- 12 Q. I just didn't want anyone to be looking
- 13 at this thinking when I think of a receipt, I'm
- 14 like I go buy something, they give me a piece of
- paper, that's a receipt. We're talking a different
- 16 receipt in the sense of ceiling application?
- 17 A. Correct. And we could even use the
- word, instead of receipts, which seems to be
- 19 confusing, we could just say received quantity and
- we would be more proper.
- 21 Q. So, what -- the ceiling calculation that
- you had suggested and which actually was adopted
- into the ceiling program was a lookback of six
- 24 weeks of what was received by the specific

- 1 pharmacy, it's calculated, and it's compared to
- 2 similar pharmacies across the chain in terms of
- 3 their receipts, their average receipts, for that
- 4 molecule?
- 5 MR. BENSINGER: Objection;
- 6 mischaracterization. You can answer.
- 7 BY THE WITNESS:
- A. I think you're close to the idea.
- 9 BY MR. SHKOLNIK:
- 10 Q. I'm trying.
- 11 A. It's drawing what a normal store should
- 12 be receiving in a six-week period of time and then
- 13 pits that against what's actually happening at that
- 14 given location. And if it's too far away from the
- norm, it becomes that 75% or it becomes over the
- 16 ceiling, if you would.
- Q. But when you're saying, and using your
- 18 phraseology, the normal store, the normal store
- 19 would be a store similar to the one we're
- 20 analyzing, not just store in Little Town in Iowa
- 21 and store in Manhattan that may have vastly
- 22 different receipts of -- received -- receivables of
- the opioids. You're using similar class stores,
- 24 are you not?

- 1 MR. BENSINGER: Objection; vague.
- 2 BY THE WITNESS:
- 3 A. No. When I -- when I say norm, normal,
- 4 I'm lumping them by volume group. So, for a store
- 5 that does 400 prescriptions, 405 would be
- 6 different. 500, you would come out with a
- 7 different number from the regression line as it
- 8 moved up the line or down the line. Not geography.
- 9 I think that's what you were getting at.
- 10 BY MR. SHKOLNIK:
- 11 Q. No. I was just talking about -- I
- 12 should have clarified it.
- So, you're looking at stores by volume.
- 14 It could be a store in Little Town in Florida that
- may take receipt of a million pills. You compare
- it to a store anywhere, could be a city or a town
- 17 somewhere else that gets a million pills. That
- 18 would be a -- that's the norm.
- 19 A. All gets baked into this equation.
- Q. Then it says up on the PowerPoint,
- 21 "Tolerance and ceiling limits are applied to
- 22 individual orders at the store level."
- So, now in the 5.5 version, what's being
- done at Walgreens, and this is sometime in 2013,

- 1 there is two different models that are running that
- 2 would have to -- that an order would be run through
- 3 before it's distributed, correct?
- 4 MR. BENSINGER: Objection; mischaracterization.
- 5 BY MR. SHKOLNIK:
- 6 Q. I'll rephrase it.
- 7 A. Thanks.
- Q. At this point in 2013 when 5.5 is
- 9 initiated, when an order is placed, before it's
- 10 received in the store, there is going to be two
- analyses applied to the order. One is the
- 12 tolerance and one is the ceiling limit. Am I
- 13 correct?
- MR. BENSINGER: Same objection. You can
- 15 answer.
- 16 BY THE WITNESS:
- 17 A. Before the order is placed, before it
- 18 becomes an order, and if it's a suggested order,
- which means it's generated by the system, it will
- take into account the ceiling value and then if
- 21 the -- and I'm going to use the term "user," but
- let's say it's the pharmacist or whoever in the
- pharmacy, operator, alters the suggested quantity
- or has created a manual order, that would be

- 1 subject then to the tolerance and, again, before it
- 2 transmits to the ceiling.
- 3 Does that make sense?
- 4 BY MR. SHKOLNIK:
- Q. Yes, yes.
- 6 A. Okay.
- 7 Q. So, now as a result of the 5.5, the
- 8 distribution center never gets an order if it
- 9 exceeds either tolerance or ceiling or both,
- irrespective if it's a computer-generated one or a
- 11 manual one?
- 12 A. If an order is -- will not be generated,
- an automated order, if it's generated, will not
- 14 exceed the ceiling limit and if the user enters a
- 15 quantity which pushes the -- that above the
- 16 ceiling, they get zero.
- If there was an order for, say, two
- 18 bottles and that was below the ceiling but the user
- 19 went and put in three, they get zero. Never goes
- 20 out.
- O. That became in effect in 2013?
- A. With this.
- 23 Q. 5.5?
- MR. BENSINGER: Objection; misstatement.

- 1 MR. SHKOLNIK: I'll rephrase it.
- 2 BY MR. SHKOLNIK:
- Q. Did that go into effect as part of 5.5,
- 4 whatever date 5.5 became effective?
- 5 MR. BENSINGER: Objection; foundation.
- 6 BY THE WITNESS:
- 7 A. That's how the ceiling works. If the
- 8 store forces a quantity -- when I say "force." If
- 9 a store manipulates a suggested quantity or enters
- 10 a quantity that's above the ceiling, no order is
- 11 placed. Zero. Whether there was one already there
- 12 for some number of packages and the additional
- 13 packages the store is requesting brings it over,
- 14 they get zero.
- 15 BY MR. SHKOLNIK:
- 16 Q. Wasn't there a period of time where the
- 17 computer would reduce it to either the ceiling or
- 18 the tolerance level or both and let the order
- 19 proceed?
- 20 A. Ceiling does not work that way. I'm not
- 21 the expert on tolerance, but I believe tolerance
- 22 would have -- there was a time when the tolerance
- would actually adjust the order and then send it.
- Q. So, when you put in the ceiling

- 1 criteria, that stopped that process from happening?
- 2 A. Yes, sir.
- MR. BENSINGER: Objection; vague.
- 4 BY MR. SHKOLNIK:
- 5 Q. Would I be correct in stating that
- 6 around the time when you released 5.5 there was a
- 7 discussion amongst the people working on this
- 8 ceiling task that the company was concerned that
- 9 its use of a reduction factor to allow an order to
- 10 go forward was somehow violative of the DEA's
- 11 recommendations?
- MR. BENSINGER: Objection; foundation.
- And, Mr. Merritello, I admonish you not
- to reveal the substance of attorney-client
- 15 communications to the extent the answer calls for
- 16 it and to confer with me as counsel to the extent
- 17 you have any question or concern as to whether in
- 18 answering the question you might reveal a
- 19 privileged attorney-client communication.
- Otherwise you may answer if you have the
- 21 question in mind.
- 22 BY MR. SHKOLNIK:
- Q. Do you want me to ask it again? I could
- 24 read it back.

- 1 A. Yes.
- MR. BENSINGER: Could you read it back.
- 3 Could you read it back.
- 4 MR. SHKOLNIK: I'm sorry. I was going to
- 5 reask the question, but read it back is fine.
- 6 (WHEREUPON, the record was read
- by the reporter as requested.)
- 8 BY THE WITNESS:
- 9 A. Was there a concern? I -- I can't
- 10 recall. I'm trying to put my arms around what that
- 11 means.
- 12 BY MR. SHKOLNIK:
- Q. Okay. Let me -- were there any
- 14 discussions among the group that were working on
- the ceiling project that went along the lines of we
- 16 have been reducing orders that exceeded tolerance
- 17 and the DEA has indicated that that's not an
- 18 appropriate way to handle an over-tolerance order
- and that now with respect to ceilings, we're going
- 20 to stop that?
- MR. BENSINGER: Again, Mr. Merritello, we
- 22 should confer before you answer if to any extent
- your answer is eliciting an attorney-client
- 24 communication.

- 1 BY THE WITNESS:
- A. I guess I don't understand, I'm sorry,
- 3 the question. I don't know.
- 4 BY MR. SHKOLNIK:
- 5 Q. If you don't understand, I have to retry
- 6 it until I get for you to understand.
- 7 Did you become aware at any point in
- 8 time, and I don't mean with conversations with
- 9 counsel in prep for a deposition, did you,
- 10 Mr. Merritello, back when you were working on the
- 11 project, the ceiling project, did you become aware
- 12 that the DEA had indicated to Walgreens and other
- 13 pharmacy distributors that the reduction of a
- 14 potentially suspicious order to a lower amount to
- avoid hitting ceiling, that that was an
- 16 inappropriate practice?
- MR. BENSINGER: So, Mr. Merritello, my
- 18 admonition is not limited to attorney-client
- 19 communications in preparing for your deposition
- 20 today.
- 21 If at the time in order to answer the
- 22 pending question you have some doubt in your mind
- as to whether in answering you'd be revealing an
- 24 attorney-client communication that took place back

- 1 at the time, I need to confer with you before you
- 2 answer and we'll go off the record. Otherwise you
- 3 can go ahead and answer.
- 4 BY THE WITNESS:
- 5 A. I guess -- I'm trying to figure. I
- 6 can't even guess at what you're -- at what I'm
- 7 being asked. There is -- your --
- 8 BY MR. SHKOLNIK:
- 9 Q. I don't want you to guess.
- 10 A. Okay.
- 11 Q. I'll rephrase. It's easier.
- 12 You were aware that prior to the ceiling
- being implemented under 5.5, one of the practices
- 14 at Walgreens was if an order was placed, whether it
- was an electronic or by a pharmacist manually, if
- 16 the order would have exceeded the tolerance, there
- was an automatic reduction of the order to a level
- 18 that was below the tolerance and allow the order to
- 19 go through? You were aware of that, correct?
- MR. BENSINGER: Objection; foundation.
- 21 BY THE WITNESS:
- 22 A. Yeah, I'm aware of how tolerance works,
- and there was a period of time when they had the
- tolerance program without the ceiling program, that

- 1 there was an adjustment made to that.
- 2 BY MR. SHKOLNIK:
- Q. Did you become aware when you got on to
- 4 the team working on ceiling that Walgreens had been
- 5 advised by DEA that the practice of making the
- 6 adjustment, the reduction down, was an
- 7 inappropriate practice?
- 8 MR. BENSINGER: Objection; vague.
- 9 BY MR. SHKOLNIK:
- 10 Q. From the DEA's perspective.
- MR. BENSINGER: Objection; vague.
- 12 BY THE WITNESS:
- 13 A. Again, the ceiling doesn't allow the
- order to go.
- 15 BY MR. SHKOLNIK:
- 16 O. I understand.
- 17 A. It vaporizes. It's just non- -- it's
- 18 non-existent.
- 19 Q. But I'm talking about before you
- 20 implemented the ceiling. Did you become aware that
- 21 the DEA had suggested to Walgreen, DEA
- representatives had suggested to Walgreens, the
- 23 practice of adjusting down as was being done with
- the tolerance program was an inappropriate

- 1 practice?
- 2 A. You're asking me that at the time that
- 3 we were putting together this program was I aware
- 4 of that?
- Q. Yes.
- 6 A. I'm going to have to tell you I don't
- 7 recall. I may have heard discussion, but...
- 8 Q. Okay. Would it be fair to say it was
- 9 not one of the program requirements that you were
- 10 charged with, that we have got to get rid of the
- 11 adjustment down component when we implement
- 12 ceiling?
- 13 A. Ceiling doesn't work that way. We
- 14 just -- this is it and no more.
- 15 Q. I understand.
- 16 A. And that was a -- that was also not a
- 17 very popular answer to the group. They didn't like
- 18 the idea that, well, what if we need to get it?
- 19 No. You got to go to the integrity team now.
- 20 Q. If someone had -- I'll withdraw the
- 21 question.
- MR. SHKOLNIK: Let's take our break now. We
- have been going at this a while. Thank you so
- 24 much.

```
THE VIDEOGRAPHER: We are off the record at
 1
 2
    10:26 a.m.
 3
                    (WHEREUPON, a recess was had
 4
                     from 10:26 to 10:37 a.m.)
         THE VIDEOGRAPHER: We are back on the record
 5
 6
    at 10:37 a.m.
 7
                    (WHEREUPON, a certain document was
 8
                     marked Walgreens-Merritello Exhibit
 9
                     No. 2: Excerpts of Personnel File,
10
                     John Merritello; not Bates
11
                     stamped.)
12
    BY MR. SHKOLNIK:
               Mr. Merritello, I'm going to hand you
13
         0.
14
    what we're marking as Exhibit 2. It's a copy of
15
    excerpts of your personnel file. Really not going
16
    to go into a lot of it. If you could --
17
         MR. SHKOLNIK: And there's no Bates -- for the
18
    people above, there is no Bates number on this
19
    because it was just produced. It hasn't been
20
    processed. But it is the personnel file.
21
    BY MR. SHKOLNIK:
22
                If you could turn to page -- in the
         0.
23
    first section on the bottom it says page 6 of 18,
24
    because there is two segments where you'll have
```

- 1 those numberings. Maybe not. Yeah. The first
- 2 section is where I'm going. 6 of 18.
- And from looking at this document, which
- 4 is highly redacted, at the bottom of the page, it
- 5 says "Annual Performance Review (Fiscal Year 13) -
- 6 Corporate, John Merritello, Jr."
- 7 Have you had an opportunity to see this
- 8 document before?
- 9 A. It looks a little familiar.
- 10 Q. As part of the yearly reviews, is it
- 11 common at Walgreens that you would put in your
- 12 assessment of what you think you accomplished and
- then your immediate supervisor here, Denman Murray,
- 14 would put in his evaluation and that's what your
- 15 yearly review would include?
- 16 A. Yes.
- 17 Q. In -- on this page, page 8 (sic) of 18,
- one section is "SOM/Tool Kit" up on the top. And
- then it says, "v5 implemented Q2, v6 and 7
- 20 implemented Q4."
- Just so we're talking the same language,
- when they say "v5 implemented Q2," what does that
- 23 mean?
- 24 A. I'm guessing that that means version 5.

- 1 O. Of the SOM?
- 2 A. Of the SOM.
- Q. And that's what we were just talking
- 4 about, the ceiling component? Am I correct?
- 5 A. Yep.
- 6 Q. And then "version 6/7 implemented Q4,"
- 7 we can go into later what 6 and 7 were, but that
- 9 just means based upon your -- what you're writing
- 9 here in your personnel file that both 5, 6 -- I'm
- sorry. Not both. 5, 6 and 7 were all implemented
- 11 fiscal year 2013 which began on September 1, 2012
- 12 and ended August 3, 2013?
- 13 A. I believe that's correct.
- Q. And when it says Q2, that would mean v5
- was implemented sometime in the winter of 2013,
- 16 correct?
- 17 A. That makes sense.
- 18 Q. The first quarter being September to
- 19 December. Quarter 2, January to, say, March or so,
- 20 correct?